



Phoebe Cheung, C. H., Alorabi, M., Hamilton, F., Takebayashi, Y., Mounsey, O., Heesom, K. J., Williams, P. B., Williams, O. M., Albur, M., MacGowan, A. P., & Avison, M. B. (2021). Trade-offs between antibacterial resistance and fitness cost in the production of metallo- $\beta$ -lactamases by enteric bacteria manifest as sporadic emergence of carbapenem resistance in a clinical setting. *Antimicrobial Agents and Chemotherapy*, 65(8), [e02412-20].  
<https://doi.org/10.1128/AAC.02412-20>

Peer reviewed version

License (if available):  
CC BY

Link to published version (if available):  
[10.1128/AAC.02412-20](https://doi.org/10.1128/AAC.02412-20)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This research was funded in whole, or in part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via American Society for Microbiology Journals at <https://doi.org/10.1128/AAC.02412-20>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

**Trade-Offs Between Antibacterial Resistance and Fitness Cost in the Production of Metallo- $\beta$ -Lactamases by Enteric Bacteria Manifest as Sporadic Emergence of Carbapenem Resistance in a Clinical Setting.**

Ching Hei Phoebe Cheung<sup>1\*</sup>, Mohammed Alorabi<sup>1,2\*</sup>, Fergus Hamilton<sup>3</sup>, Yuiko Takebayashi<sup>1</sup>, Oliver Mounsey,<sup>1</sup> Kate J. Heesom<sup>4</sup>, Philip B. Williams<sup>5</sup>, O. Martin Williams<sup>5</sup>, Mahableshwar Albur<sup>3</sup>, Alasdair P. MacGowan<sup>3</sup>, Matthew B. Avison<sup>1#</sup>.

<sup>1</sup>School of Cellular & Molecular Medicine, University of Bristol, United Kingdom.

<sup>2</sup>Department of Biotechnology, Faculty of Sciences, Taif University, Kingdom of Saudi Arabia.

<sup>3</sup>Department of Microbiology, Infection Sciences, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.

<sup>4</sup>Bristol Proteomics Facility, University of Bristol. United Kingdom.

<sup>5</sup>Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, United Kingdom.

\*Ching Hei Phoebe Cheung and Mohammed Alorabi contributed equally to this work. Ching Hei Phoebe Cheung finished the work for publication and so is named first author.

#Correspondence: Matthew B. Avison, School of Cellular & Molecular Medicine, Biomedical Sciences Building, University Walk, Bristol. BS81TD. UK. bimba@bris.ac.uk.

Running Header: Fitness/Resistance Trade-offs for MBL Carriage

## Abstract

Meropenem is a clinically important antibacterial reserved for treatment of multi-resistant infections. In meropenem-resistant bacteria of the family Enterobacterales, NDM-1 is considerably more common than IMP-1, despite both metallo- $\beta$ -lactamases (MBLs) hydrolysing meropenem with almost identical kinetics. We show that *bla*<sub>NDM-1</sub> consistently confers meropenem resistance in wild-type Enterobacterales, but *bla*<sub>IMP-1</sub> does not. The reason is higher *bla*<sub>NDM-1</sub> expression because of its stronger promoter. However, the cost of meropenem resistance is reduced fitness of *bla*<sub>NDM-1</sub> positive Enterobacterales. In parallel, from a clinical case, we identified multiple *Enterobacter* spp. isolates carrying a plasmid-encoded *bla*<sub>NDM-1</sub> having a modified promoter region. This modification lowered MBL production to a level associated with zero fitness cost but, consequently, the isolates were not meropenem resistant. However, we identified a *Klebsiella pneumoniae* isolate from this same clinical case carrying the same *bla*<sub>NDM-1</sub> plasmid. This isolate was meropenem resistant despite low-level NDM-1 production because of a *ramR* mutation, reducing envelope permeability. Overall, therefore, we show how the resistance/fitness trade-off for MBL carriage can be resolved. The result is sporadic emergence of meropenem resistance in a clinical setting.

## Introduction

$\beta$ -Lactamases are the most frequent cause of  $\beta$ -lactam resistance among Gram-negative bacteria. In  $\beta$ -lactamases of molecular classes A, C and D, an active site serine catalyses hydrolysis of the  $\beta$ -lactam ring. Members of class B utilize zinc ions in catalysis and are known as metallo- $\beta$ -lactamases (MBLs). Based on their sequence homology, MBLs are classified into three subclasses: B1, B2 and B3 (1). Chromosomally encoded MBLs belonging to subclasses B2 and B3 have been isolated from environmental and opportunistic pathogenic bacteria such CphA (*Aeromonas hydrophila*) (2), L1 (*Stenotrophomonas maltophilia*) (3), IND (*Chryseobacterium indologenes*) (4), and Sfh-1 (*Serratia fonticola*) (5). However, the most common MBLs in human pathogens are from subclass B1 and are encoded on mobile genetic elements, particularly VIM (6), IMP (7), and NDM (8). These enzymes can efficiently catalyse the hydrolysis of all clinically relevant  $\beta$ -lactams except the monobactams (1).

The genes encoding VIM-1 and IMP-1 are held within class 1 integrons as gene cassettes (6,7). Integrons are gene capture systems consisting of a 5' conserved sequence including *intI*, encoding an integrase enzyme, an array of gene cassettes, and a 3' conserved sequence. Gene cassettes are promoter-less and consist of an open reading frame and an adjacent recombination site, *attC*, specifically recognized by the integrase enzyme. A common promoter (*P<sub>c</sub>*) located within the *intI* sequence directs expression of all gene cassettes in an integron (9). There are essentially three strengths of *P<sub>c</sub>*: *P<sub>cS</sub>* – strong, *P<sub>cW</sub>* – weak, and *P<sub>cH</sub>* – intermediate (10).

The *bla<sub>NDM-1</sub>* gene is not a gene cassette but has been mobilised by an insertion sequence (IS) element, *IS<sub>Aba125</sub>* (11). This mobilisation also drives expression of *bla<sub>NDM-1</sub>*, because *IS<sub>Aba125</sub>* carries an outward facing promoter, *P<sub>out</sub>* (12).

In a recent UK study, NDM-1 was found to be the dominant MBL in carbapenem resistant Enterobacterales clinical isolates, with IMP-1 not being found at all (13). One possible explanation is that NDM-1 is a lipoprotein and has evolved to perform well in the sort of low zinc environment often seen at sites of infection (14), something which is enhanced in various NDM variants, particularly NDM-4 (15). However, it is possible that positive selection for NDM-1 production is driven by something more fundamental. There is some evidence that IMP-1-encoding plasmids only confer borderline resistance to carbapenems in *E. coli* even when zinc concentration are high (e.g. as seen in Ref 16), whereas minimum inhibitory concentrations (MICs) of carbapenems against *E. coli* transconjugants carrying NDM-1 plasmids are much higher (e.g. as seen in Ref 8). We hypothesise that a more consistent ability to confer carbapenem resistance is part of the reason why NDM-1 is dominant over IMP-1 among carbapenem resistant isolates. If correct, this would imply that the levels of active enzyme produced are frequently greater for NDM-1- than for IMP-1-positive Enterobacterales because, catalytically, the enzymes are very similar (8).

The aims of the work presented here was to test the hypothesis that NDM-1 and IMP-1 confer different carbapenem MICs, because they are produced at different levels from their native expression environments, and that NDM-1 more commonly confers carbapenem resistance than IMP-1. Furthermore, we have investigated the fitness trade-offs that come in to play when higher level MBL production is necessary to confer resistance. Finally, we report a clinical case demonstrating how these fitness trade-offs manifest in the real world.

## Results and Discussion

*bla<sub>NDM-1</sub>* is expressed at higher levels than *bla<sub>IMP-1</sub>* and confers meropenem resistance in *Enterobacterales* clinical isolates.

A blastn search of GenBank using the nucleotide sequences of *bla<sub>IMP-1</sub>* and *bla<sub>NDM-1</sub>* revealed that, of entries that matched with 100% coverage and identity, *E. coli* ( $\chi^2=9.82$ ,  $p<0.005$ ) and *Klebsiella* spp. ( $\chi^2=12.72$ ,  $p<0.0005$ ) are more likely to carry *bla<sub>NDM-1</sub>* than *bla<sub>IMP-1</sub>*. This analysis is supported by global surveillance data from clinical isolates. For example, from a recent SENTRY study where, of 1298 carbapenem resistant *Enterobacterales* analysed in 2014-16, *bla<sub>NDM</sub>* positivity was 12.7% whilst *bla<sub>IMP</sub>* positivity was 0.4% (17). In contrast, the non-*Enterobacterales* *Pseudomonas* spp. is more likely to carry *bla<sub>IMP-1</sub>* than *bla<sub>NDM-1</sub>* ( $\chi^2=30.18$ ,  $p<0.00001$ ).

There may be many reasons why one gene conferring resistance to an antibacterial drug disseminates more widely than another, but we sought to test the hypothesis that *bla<sub>NDM-1</sub>* is dominant over *bla<sub>IMP-1</sub>* in carbapenem resistant *Enterobacterales* because only *bla<sub>NDM-1</sub>* reliably confers carbapenem resistance. The *bla<sub>NDM-1</sub>* gene is almost exclusively found downstream of an IS*Aba125* sequence, which provides an outward facing promoter, P<sub>out</sub>, which drives *bla<sub>NDM-1</sub>* expression (11). In contrast, *bla<sub>IMP-1</sub>* is encoded as an integron gene cassette (7), and so can be present downstream of several different promoter (P<sub>c</sub>) sequences (10). Of the 26 *bla<sub>IMP-1</sub>* GenBank entries involving *E. coli*, *Klebsiella* spp. and *Enterobacter* spp. where sufficient sequence was present to identify the P<sub>c</sub> promoter variant, 24/26 were intermediate strength as previously defined (10) and of these, ten were P<sub>c</sub>H1 variants (**Table S1**). We therefore chose to compare the impact of carrying *bla<sub>IMP-1</sub>*

located downstream of the P<sub>CH1</sub> promoter with *bla*<sub>NDM-1</sub> located downstream of P<sub>out</sub> from IS*Aba125* on susceptibility to the carbapenem meropenem.

Thirteen out of thirteen *bla*<sub>NDM-1</sub> Enterobacterales clinical isolate transformants tested were meropenem resistant, defined using clinical breakpoints, but only 1/13 *bla*<sub>IMP-1</sub> transformants (**Table S2**). These data support our primary hypothesis, that NDM-1 more readily confers meropenem resistance than IMP-1 in the Enterobacterales.

IMP-1 and NDM-1 are, in terms of meropenem catalytic efficiency, very similar enzymes (8), so our next hypothesis was that more NDM-1 is produced than IMP-1 in cells, explaining the difference in meropenem MIC. This hypothesis was also supported by experiment; the amount of meropenem hydrolysing activity in cell extracts of representative *bla*<sub>NDM-1</sub> transformants of *E. coli*, *K. pneumoniae* and *Enterobacter (Klebsiella) aerogenes* was 3 to 6-fold higher than in *bla*<sub>IMP-1</sub> transformants ( $p < 0.002$  for each). As expected, elevated meropenem hydrolysing activity was due to greater production of NDM-1 than IMP-1 protein as measured using LC-MS/MS proteomics (**Fig. 1**).

Changing the ribosome binding sequence upstream of *bla*<sub>NDM-1</sub> to be identical to that found upstream of *bla*<sub>IMP-1</sub> did not significantly reduce NDM-1 production or meropenem hydrolysing activity. However, generating the N\* variant, by replacing the entire *bla*<sub>NDM-1</sub> upstream sequence with that upstream of *bla*<sub>IMP-1</sub>, reduced NDM-1 production to be very similar to that of IMP-1 in all three species (**Fig. 1**).

*The correlation between high gene expression and fitness cost when carrying bla<sub>NDM-1</sub> is associated with amino acid starvation.*

We next investigated whether the greater production of NDM-1 relative to IMP-1 imposes a fitness cost. Using pairwise competition experiments, where transformants were directly competed over 4 days in the absence of  $\beta$ -lactams, we showed that there is no cost of carrying *bla*<sub>IMP-1</sub> in *E. coli* and *K. pneumoniae*, but there was a significant cost of carrying *bla*<sub>NDM-1</sub> in both species (**Table 1**).

Higher production of NDM-1 versus IMP-1 could impose a fitness cost because of depletion of resources required to make the additional MBL (e.g. amino acids, energy and zinc), or it could be due to some toxicity that the MBL imposes, as has been seen in some cases, e.g. SPM and VIM, previously (18). To differentiate between these possibilities, we investigated the physiological impact of carrying *bla*<sub>IMP-1</sub> or *bla*<sub>NDM-1</sub> in *E. coli*. To do this, we used LC-MS/MS proteomics to quantify steady state protein abundance differences in transformants.

Of 1390 proteins identified and quantified in the *bla*<sub>IMP-1</sub> vs plasmid only control comparison, 66 were significantly up or down regulated (**Table S3**) but Chi squared analysis did not reveal clustering of these proteins into any KEGG functional group, suggesting that there is little concerted physiological response to carrying *bla*<sub>IMP-1</sub> (**Table S4**). The *bla*<sub>NDM-1</sub> versus control comparison identified and quantified 1670 proteins, of which 88 were differentially regulated (**Table S5**). In this case Chi squared analysis did identify clustering (**Table S6**) of these regulated proteins into a specific KEGG pathway: eco00260, glycine, serine, and threonine metabolism. Upregulated proteins include the committed enzymes GlyA (19), SerA (20), ThrC (21), and IlvA, which directs these amino acids into other amino acid biosynthetic pathways (22). Therefore, production of NDM-1, which is approximately 6-fold more than production of IMP-1 in *E. coli* (**Fig. 1**), comes with a significantly fitness cost



(Table 1), which is associated with regulatory signals of amino acid starvation (Tables S3-S6).

#### *Increasing IMP-1 production increases fitness cost*

To further test the hypothesis that the amount of MBL protein production is a major part of the fitness cost imposed by carrying MBL genes and to exclude any NDM-1 specific effects, we aimed to increase IMP-1 production. To do this we turned to our recently reported *bla*<sub>IMP-1</sub> synonymous lysine codon variant, IMP-1-KV where 17 AAA lysine codons were converted to the alternative synonymous codon, AAG (23). LC-MS/MS proteomics showed that the amount of IMP-1 produced from the variant *bla*<sub>IMP-1-KV</sub> was 2.2-fold ( $p=0.005$ ) more than from wild-type *bla*<sub>IMP-1</sub> in *E. coli* (Fig. 2). As hypothesised, this increase in IMP-1 protein production was associated with an increase in fitness cost, which was approximately 7% per day in *E. coli* and approximately 20% per day in *K. pneumoniae* ( $p<0.001$  for both comparisons) (Table 1). We attempted to repeat this experiment by cloning *bla*<sub>IMP-1</sub> downstream of a strong integron promoter, which drives high-level gene expression, but very few *E. coli* transformants were recovered. In all cases, the transformants had mutations upstream of *bla*<sub>IMP-1</sub> expected to reduce gene expression, e.g. those affecting the -35 or -10 promoter sequences or the spacing in between. Accordingly, we conclude that the fitness cost of carrying this highly expressed form of *bla*<sub>IMP-1</sub> is too great for transformants to bear.

*Reduced NDM-1 production due to rearrangements in the bla<sub>NDM-1</sub> promoter region explains lack of meropenem resistance in Enterobacter spp. isolates from a clinical case.*

A patient was admitted directly to the intensive care unit after developing a small bowel obstruction and an aspiration pneumonia. Bronchoalveolar lavage grew *Citrobacter freundii*, *K. pneumoniae* and *Bacteroides vulgatus*. The patient was initially treated with piperacillin-tazobactam and azithromycin and noted to have a strangulated inguinal hernia which was repaired. Two days after admission, the patient was escalated to meropenem due to continued fever. Vancomycin was added for a possible coagulase negative *Staphylococcus* spp. line infection. They continued to require ventilation and a tracheostomy was performed on day 7. By 20 days after admission, symptoms had resolved and C-reactive protein had fallen to 10 from 368 mg/L on admission, and meropenem was stopped.

Five days later, fever restarted, and a sputum sample grew *K. pneumoniae* resistant to piperacillin-tazobactam and ciprofloxacin, but Extended-Spectrum  $\beta$ -Lactamase (ESBL) negative and susceptible to third-generation cephalosporins. Ceftazidime and vancomycin were started. After 6 days of ceftazidime, a routine multi-resistant coliform screen of the patient's tracheostomy site noted a ceftazidime resistant *Enterobacter* spp. (Ent1). This was ESBL positive and had a multi-drug resistance phenotype (**Table S7**). Due to an apparently raised meropenem MIC, a Cepheid Xpert-Carba R PCR test was performed, suggesting the presence of *bla<sub>NDM</sub>*. Despite this, Ent1 was not meropenem resistant and so ceftazidime treatment was switched to meropenem. After 10 days of meropenem, the patient improved, and antibiotic therapy was discontinued. Routine screens continued to isolate *Enterobacter* spp. with the same resistance pattern and being *bla<sub>NDM</sub>* positive (e.g. Ent2) but 12 days

after the isolation of Ent1, another routine screen identified an ESBL negative *K. pneumoniae*, which was fully resistant to meropenem (KP3), as well as to third-generation cephalosporins, piperacillin-tazobactam and ciprofloxacin (**Table S7**). The Cepheid Xpert-Carba also identified *bla*<sub>NDM</sub> in KP3. The patient, however, remained well and continued off antibiotics and was discharged to the surgical ward. Subsequent routine screens continued to identify this meropenem resistant *K. pneumoniae* and the *bla*<sub>NDM</sub> positive *Enterobacter* spp. that was not meropenem resistant and specialist infection control precautions were continued.

Whole genome sequence (WGS) analysis of the *Enterobacter* spp. isolates Ent1 and Ent2 showed them to be *Enterobacter hormaechei* and confirmed that *bla*<sub>NDM-1</sub> is present on the same IncFIB(K) plasmid in both. The plasmid was assembled into a single contig of 84,659 nt carrying genes conferring resistance to amikacin/ciprofloxacin (*aacA4-cr*), rifampicin (*arr-3*), co-trimoxazole (*sul1*) and streptomycin (*aadA1*), all part of the same complex class 1 integron alongside *bla*<sub>NDM-1</sub>. Otherwise, on the chromosome, other relevant resistance genes carried by Ent1 and Ent2 were to ampicillin (*bla*<sub>TEM-1</sub>), and the expected ESBL (*bla*<sub>CTX-M-15</sub>). The isolates also carried chromosomal mutations in *gyrA* (Ser83Ile) and *parC* (Ser80Ile) causing ciprofloxacin resistance. Collectively this acquired resistance genotype explains the antibiograms of Ent1 and Ent2, except for the fact that meropenem resistance should have been provided by the *bla*<sub>NDM-1</sub> gene but was not.

LC-MS/MS proteomics revealed that NDM-1 production was the same in Ent1 and Ent2. The amount normalised to ribosomal proteins was 0.41 +/- 0.03 (mean +/- SD), which was not significantly different ( $p=0.13$ ) from the amount of IMP-1 produced from its native P<sub>CH1</sub> promoter in *bla*<sub>IMP-1</sub> transformants of *E. coli* and *K. pneumoniae* described above (0.49 +/- 0.18, **Fig. 1**). In contrast, NDM-1 production in Ent1 and

Ent2 was significantly different from ( $p<0.0005$ ), and approximately 6-fold less than NDM-1 production in transformants of *E. coli* and *K. pneumoniae* where *bla*<sub>NDM-1</sub> was expressed from the typical IS*Aba125* P<sub>out</sub> promoter (3.24 +/- 0.69, **Fig. 1**). This low-level production of NDM-1 in Ent1 and Ent2 likely explains why these isolates are not meropenem resistant (MIC<4 mg/L), as seen for *bla*<sub>IMP-1</sub> transformants (**Table S2**).

To explain the reason for low-level NDM-1 production in Ent1 and Ent2, we compared the sequence upstream of *bla*<sub>NDM-1</sub> in these two isolates with those from *E. coli* IR10, the source of the recombinant plasmids used above, and from *K. pneumoniae* KP05-506, which is the original isolate from which *bla*<sub>NDM-1</sub> was identified (8). We found a significant rearrangement immediately adjacent to the IS*Aba125* P<sub>out</sub> promoter in Ent1 and Ent2 (**Fig. 3**). There has been an insertion of an element containing a truncated *bla*<sub>OXA-10</sub> gene.

The upstream variation seen in Ent1 is rare but not unique. It matched to 14 NCBI database entries reporting isolates collected in China, Taiwan, Japan, Pakistan, and the UK (**Table S8**). Notably, but not commented on by the authors, an *E. coli* transconjugant carrying plasmid pLK78, encoding *bla*<sub>NDM-1</sub> with this *bla*<sub>OXA-10</sub> upstream insertion, was not meropenem resistant (24). Moreover, isolates from Pakistan where the *bla*<sub>OXA-10</sub> insertion upstream of *bla*<sub>NDM-1</sub> was identified in several related plasmids (25) were originally collected in 2010 and the authors noted that 53% of NDM-1 producing isolates were meropenem susceptible (26).

*Low-level NDM-1 production confers meropenem resistance in a background with reduced envelope permeability.*

Isolate KP3, from the same clinical case, was meropenem resistant. LC-MS/MS proteomics analysis confirmed that KP3 produced NDM-1 at the same level as Ent1 and Ent2. WGS showed that as well as carrying *bla*<sub>NDM-1</sub>, *aacA4-cr*, *sul1*, *arr-3* and *aadA1* on an IncFIB(K) plasmid identical to that found in Ent1 and Ent2, KP3 carried *bla*<sub>TEM-1</sub> and *bla*<sub>OXA-9</sub>, found together on a second plasmid, plus the chromosomal *bla*<sub>SHV-1</sub>. KP3 also has Ser83Phe and Asp87Ala mutations in GyrA plus a Ser80Ile mutation in ParC explaining ciprofloxacin resistance.

The  $\beta$ -lactamases produced by KP3 in addition to NDM-1 cannot explain the very much higher MIC of meropenem against KP3 versus Ent1 and Ent2. Analysis of KP3 WGS data for known factors that contribute to carbapenem resistance revealed only one: that KP3 is a *ramR* mutant, having an 8 nt insertion into *ramR* after nucleotide 126, causing a frameshift. We have shown that loss of RamR in *K. pneumoniae* leads to enhanced AcrAB-TolC efflux pump production, reduced OmpK35 porin production, and enhanced carbapenem MICs in the presence of weak carbapenemases (27). Hence this mutation in KP3 enhances the meropenem MIC against KP3, making it resistant despite low-level production of NDM-1 due to modification of the IS*Aba125* outward facing promoter region by insertion of a truncated *bla*<sub>OXA-10</sub>.

## Conclusions

Overall, we have observed that modest expression of *bla*<sub>IMP-1</sub> from a native intermediate strength integron common promoter (PcH1), which is regularly seen in *bla*<sub>IMP-1</sub> clinical isolates, does not provide meropenem resistance in representative Enterobacterales strains, but neither does it cause a fitness cost. In contrast, *bla*<sub>NDM-1</sub>

is expressed at higher levels from its native *ISAba125* outward facing promoter and this gives higher meropenem MICs, confers resistance as defined by clinical breakpoints, but this comes with a significant fitness cost. A fitness cost associated with carrying *bla<sub>NDM-1</sub>* was also found in a previous report (28). We conclude that the likely reason for this fitness cost is that NDM-1 is produced at high levels when *bla<sub>NDM-1</sub>* is expressed from its native promoter. The obvious explanation is that producing a large amount of a non-native protein results in amino acid depletion, which drives the cell to switch on amino acid biosynthetic pathways, which was observed in our proteomic analysis. Whilst this maintains the supply of amino acids for protein synthesis, it diverts carbon that would otherwise be available to other processes required for cell growth. This effect may be exaggerated in the case of NDM-1, since it is targeted to the outer membrane, where it can be lost within microvesicles (29). There was no evidence of zinc starvation stress in our proteomics data, though presumably at lower zinc concentrations the fact that NDM-1 is a zinc containing enzyme could exacerbate the fitness cost. Our fitness assays were performed using a medium containing 6.2  $\mu$ M zinc and the broth used to perform MIC testing and proteomics contains  $\sim$ 4  $\mu$ M zinc (30). The normal human serum concentration of zinc is  $\sim$ 12  $\mu$ M (31) but clearly, long term selection pressure on Enterobacterales is perhaps more likely to occur outside the human body, where zinc concentrations may be very much lower even than in our assays.

Our findings provide a real-world example of fitness/resistance trade-offs. It may be that the reason for *bla<sub>NDM-1</sub>* being so common in carbapenem resistant Enterobacterales is repeated selective pressure via carbapenem use, driving its presence despite the cost. Alternatively, natural plasmids or certain strains carrying them, or even variant *bla<sub>NDM</sub>* genes encoded on these plasmids, might have

309 accumulated mutations that compensate for reduced fitness. This could come  
310 without the expense of reduced carbapenem MICs, e.g., if an NDM produced at  
311 lower levels was a variant more efficient at catalysing the hydrolysis of meropenem.  
312 But in the case reported here, we have identified the insertion of a truncated *bla*<sub>OXA-10</sub>,  
313 damaging the *bla*<sub>NDM-1</sub> promoter region and reducing NDM-1 production in  
314 *Enterobacter* spp. isolates from a clinical case, a genetic arrangement found in  
315 commensal carriage Enterobacterales isolates from as far back as 2010 (26).

316 Low-level NDM-1 producers avoid the fitness cost associated with wild-type *bla*<sub>NDM-1</sub>  
317 carriage but, consequently, are not meropenem resistant. Though they remain  
318 cephalosporin resistant, and so are likely to be maintained in an environment where  
319 cephalosporins are used. This highlights a potential infection control issue where  
320 phenotypic meropenem resistance is necessary for a positive screening outcome. As  
321 seen here, the isolates Ent1 and Ent2 were still identified as being of interest due to  
322 extra vigilance in respect of a seriously ill patient. With less vigilance, it may have  
323 been that the only notice of the presence of an NDM-1 producing isolate in or around  
324 this patient would have been following mobilisation of the *bla*<sub>NDM-1</sub> encoding plasmid  
325 into the *ramR* mutant *K. pneumoniae* with reduced envelope permeability, to create  
326 meropenem resistant isolate KP3. This ability of reduced envelope permeability to  
327 enhance meropenem MIC against a low-level MBL producer may also explain our  
328 finding that *bla*<sub>IMP-1</sub> is more common in *P. aeruginosa*, a species renowned for having  
329 much lower envelope permeability than wild-type Enterobacterales (32). In the  
330 context of “under the radar” NDM-1 production defined here, which also relies on  
331 reduced envelope permeability, we show that sudden emergence of clinically-  
332 relevant meropenem resistance can occur in a manner that is not dependent on new

importation events and so cannot be prevented by standard infection control measures.

## **Experimental**

### *Bacteria Used and Susceptibility Testing Assays*

Bacterial strains used in the study were *E. coli* MG1655 (33) and a collection of human clinical isolate from urine (a gift from Dr Mandy Wooton, Public Health Laboratory for Wales), a human clinical isolate of *K. aerogenes*, NDM-1 producing isolates of *E. coli* IR10 and *K. pneumoniae* KP05\_506 (gifts from Prof T Walsh, University of Oxford), and *K. pneumoniae* strains SM, ECL8 and NCTC 5055 (34). Antibiotic susceptibility was determined using disc testing or broth microdilution MIC assays according to EUCAST guidelines. Cation-Adjusted Mueller-Hinton Broth (CAMHB) was purchased from Sigma.

### *Molecular Biology*

Creation of pSUHIMP, being the cloned *bla*<sub>IMP-1</sub> gene downstream of a native PcH1 was via PCR using template DNA from *P. aeruginosa* clinical isolate 206-3105A (a gift from Dr Mark Toleman, Department of Medical Microbiology, Cardiff University). The sequence of plasmid pYUI-1, the *bla*<sub>IMP-1</sub> encoding plasmid from this isolate has been deposited under GenBank accession number MH594579. PCR used a forward primer targeting the 5' end of the PcH1 promoter (5'-ACCCAGTGGACATAAGCCTGTTTCGGTTCGTAAACT-3') and a reverse primer targeting the 5' end of a *bla*<sub>OXA-1</sub> gene cassette, which is downstream of *bla*<sub>IMP-1</sub> in this isolate (5'-AGCGAAGTTGATATGTATTGTG-3'). The PCR amplicon was TA



cloned into the pCR2.1TOPO cloning vector (Invitrogen), removed with EcoRI and ligated into EcoRI linearized broad host range p15A-derived vector pSU18 (35). Site directed mutagenesis to create pSUHIMP-KV containing 14 AAA-AAG transitions was performed using the methods and primers previously reported (23). Creation of pSUNDM, being the cloned *bla*<sub>NDM-1</sub> gene downstream of its native *ISAb<sub>a</sub>125* promoter in plasmid pSU18 has been reported previously (36). Site directed mutagenesis using pSUNDM as the template was performed using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent, UK) according to the manufacturer's instructions. The aim was to convert the native ribosome binding site upstream of *bla*<sub>NDM-1</sub> (AAAAGGAAAACTTGATGAGCAAGTTATCT) to be the same as that upstream of *bla*<sub>IMP-1</sub> (AAAAGGAAAAGTATGAGCAAGTTATCT – differences underlined), using the mutagenic primer 5'-GGGGTTTTTAATGCTGAATAAAAGGAAAAGTATGGAATTGCCCAAT-3'. The resultant plasmid was named pSUNDM-RBS. Switching the entire upstream sequence from the ATG of *bla*<sub>NDM-1</sub> to be the same as *bla*<sub>IMP-1</sub> was performed by gene synthesis recreating the entire pSUNDM insert sequence, but with the same upstream sequence carried in pSUHIMP. The resultant plasmid was named pSUNDM-N\*

### *Proteomic Analysis*

A volume of 1 ml of overnight liquid culture was transferred to a 50 ml of fresh CAMHB and incubated at 37°C until an OD<sub>600</sub> of 0.5-0.6 was achieved. Samples were centrifuged at 4,000 rpm for 10 min at 4°C and the supernatants discarded. Cells were re-suspended into lysis buffer (35 ml of 30mM Tris-HCl pH 8) and broken by sonication using a cycle of 1 s on, 1 s off for 3 min at amplitude of 63% using a

Sonics Vibracell VC-505TM (Sonics and Materials Inc., Newton, Connecticut, USA). This was followed by centrifugation at 8000 rpm (Sorval RC5B PLUS using an SS-34 rotor) for 15 min at 4°C to pellet non-lysed cells. Soluble proteins were concentrated to a volume of 1 ml using centrifugal filter units (AMICON ULTRA-15, 3 KDa cutoff). Then, the concentration of the proteins in each sample was measured using Biorad Protein Assay Dye Reagent Concentrate according to the manufacturer's instructions and normalised. LC-MS/MS was performed and analysed as described previously (37) using 5 µg of protein for each run. Analysis was performed in triplicate, each from a separate batch of cells. Protein abundance was normalised using the average abundance of ribosomal proteins, unless stated in the text.

#### *Measurement of meropenem hydrolysis*

Twenty microlitres of concentrated total cell protein (prepared and assayed for concentration as above) was transferred to 180 µl of 50 mM HEPES (pH 7.5) containing 50 µM ZnSO<sub>4</sub> and 100 µM meropenem. Change of absorbance was monitored at 299 nm over 10 min. Specific enzyme activity (pmol meropenem hydrolysed per milligram of protein per second) in each extract was calculated using 9600 M<sup>-1</sup> as the extinction coefficient of meropenem and dividing enzyme activity with the total amount of protein in each assay.

#### *Pairwise Fitness Cost Experiments*

Pairwise competition experiments were performed by using M9 minimal medium to evaluate the fitness cost of carrying pSUHIMP, pSUHIMP-KV or pSUNDM, each relative to the carriage of the pSU18 cloning vector alone. Initially, liquid cultures of

both transformants in the pairwise competition were established separately in LB broth at 37°C with shaking at 160 rpm. Then, 5 µl of each overnight liquid culture was inoculated into 10 ml M9 minimal medium separately in flasks and incubated as above for 24 h as before. After this incubation, 5 µl of each overnight M9 minimal medium was again inoculated separately into 10 ml M9 minimal medium as before and grown overnight. The next day, for each competing bacterium, 75 µl of the previous day's culture was inoculated into fresh 15 ml M9 minimal medium to obtain a mixed culture (day one). After 24 h of incubation, 150 µl of the mixed culture was transferred into a fresh 15 ml M9 minimal medium to obtain the day-two culture. Then, this step was performed successively until the day-four mixed liquid culture was attained. For each pairwise competition experiment, the above process was carried out six times in parallel and on each day, the colony forming units per ml (cfu/ml) of the two bacteria was counted in triplicate using LB agar selective for the cloning vector (the total count of both competitors, as both are chloramphenicol resistant) and agar containing 20 mg/L ceftazidime (to count bacteria producing IMP-1 or NDM-1). The pSU18 containing transformant count was calculated by subtracting the pSUHIMP or pSUNDM containing transformant count from the total count of bacteria in the competition.

The fitness cost of the resistant strain relative to the sensitive strain was estimated by calculating the Malthusian parameter of the strain (M) as described (38):

$$M = \ln(N_1/N_0)$$

Where  $N_0$  indicates the density of the strain at the start of the day (cfu/ml) and  $N_1$  represents the density of the strain at the end of the day (cfu/ml).

Then the selection rate for a pairwise competition is calculated as below:

430  $W = M1/M2$

431 Where M1 represents growth of the sensitive strain and M2 refers to growth of the  
432 resistant strain. If R is positive, then  $M1 > M2$  which implies that the sensitive strain  
433 grows faster than the resistant strain and as a result has a fitness advantage and  
434 vice versa.

435 For each day of competition, 36 values are achieved as for each pair-wise  
436 competition there are 6 R values and there are 6 competitions each day (6 mixed  
437 cultures a day).

438 Differences in the two sets of data for each pairwise comparison were assessed  
439 using mean and standard deviation of R, and an unpaired t-test (with Welch's  
440 correction) was used to assess the statistical significance of the differences  
441 observed.

442

#### 443 *Analysis to identify clustering of differentially regulated proteins*

444 The KEGG Mapper tool: [http://www.genome.jp/kegg/tool/map\\_pathway2.html](http://www.genome.jp/kegg/tool/map_pathway2.html) was  
445 used. We searched against *E. coli* MG1655 (organism: eco) and entered a list of the  
446 Uniprot accession numbers for the differentially regulated proteins. As a control, an  
447 equal number of *E. coli* MG1655 Uniprot accession numbers was randomly selected  
448 and entered in the KEGG Mapper as above. To determine the total number of  
449 proteins in the *E. coli* MG1655 proteome that fall into each KEGG, the entire Uniprot  
450 MG1655 accession number list was used to feed the KEGG Mapper tool. These  
451 values were used to perform a  $\chi^2$  analysis considering the significance of clustering  
452 of differentially regulated proteins by reference to random proteins into a KEGG  
453 functional group. To maximise specificity, the comparison with random proteins was

performed 10 times, each with a different list of random proteins and the result reported was the lowest  $\chi^2$  value obtained across all 10 comparisons.

#### *WGS and data analysis*

Genomes were sequenced by MicrobesNG (Birmingham, UK) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic (39) and assembled into contigs using SPAdes (40) 3.13.0 (<http://cab.spbu.ru/software/spades/>) and contigs were annotated using Prokka (41). The presence of plasmids and resistance genes was determined using PlasmidFinder (42) and ResFinder 2.1 (43).

#### *Ethics Statement.*

This project is not part of a trial or wider clinical study requiring ethical review. The patient signed to give informed consent that details of their case be referred to in a publication and for educational purposes.

#### **Acknowledgements**

This work was funded by grant MR/N013646/1 to M.B.A., O.M.W., A.P.M. and K.J.H. and grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research, and grant MR/T005408/1 to P.W. and M.B.A. from the Medical Research Council. M. Alorabi. was supported by a Postgraduate Scholarship from the Cultural Bureau of the Kingdom of Saudi Arabia. F.H. was

supported by a clinical fellowship from the Wellcome Trust. Genome sequencing was provided by MicrobesNG (<http://www.microbesng.uk>). We are grateful to Dr Aisha Alamri and to Ka Wang Mak, both lately of the School of Cellular & Molecular Medicine, University of Bristol for constructing pSUHIMP and attempting to clone *bla<sub>IMP-1</sub>* downstream of PcS.

**The authors declare no conflicts of interest.**

#### **Author Contributions**

Conceived the Study: M.B.A., F.H.

Collection of Data: C.C., M. Alorabi, Y.T., O.M, K.J.H, F.H., supervised by M. Albur, A.P.M., M.B.A.

Cleaning and Analysis of Data: C.C., M. Alorabi, Y.T., O.M, K.J.H, F.H., O.M.W., P. W. supervised by M. Albur, A.P.M., M.B.A.

Initial Drafting of Manuscript: M. Alorabi, F.H., M.B.A.

Corrected and Approved Manuscript: All Authors.

## References

1. Walsh TR. Emerging carbapenemases: a global perspective. *Int J Antimicrob Agents*. 2010;36 Suppl 3:S8-14
2. Massidda O, Rossolini GM, Satta G. The *Aeromonas hydrophila* *cphA* gene: molecular heterogeneity among class B metallo-beta-lactamases. *J Bacteriol*. 1991;173:4611-7
3. Walsh TR, Hall L, Assinder SJ, Nichols WW, Cartwright SJ, MacGowan AP, Bennett PM. Sequence analysis of the L1 metallo-beta-lactamase from *Xanthomonas maltophilia*. *Biochim Biophys Acta*. 1994;1218:199-201
4. Bellais S, Léotard S, Poirel L, Naas T, Nordmann P. Molecular characterization of a carbapenem-hydrolyzing beta-lactamase from *Chryseobacterium* (*Flavobacterium*) *indologenes*. *FEMS Microbiol Lett*. 1999;171:127-32.
5. Saavedra MJ, Peixe L, Sousa JC, Henriques I, Alves A, Correia A. Sfh-I, a subclass B2 metallo-beta-lactamase from a *Serratia fonticola* environmental isolate. *Antimicrob Agents Chemother*. 2003;47:2330-3
6. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini GM. Cloning and characterization of *bla*VIM, a new integron-borne metallo-beta-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother*. 1999;43:1584-90.
7. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. *Antimicrob Agents Chemother*. 1994;38:71-8.
8. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-beta-lactamase gene, *bla*(NDM-1), and a novel

- erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother.* 2009;53:5046-54
9. Gillings MR. Integrons: past, present, and future. *Microbiol Mol Biol Rev.* 2014;78:257-77
10. Jové T, Da Re S, Denis F, Mazel D, Ploy MC. Inverse correlation between promoter strength and excision activity in class 1 integrons. *PLoS Genet.* 2010;6:e1000793
11. Toleman MA, Spencer J, Jones L, Walsh TR. *bla*<sub>NDM-1</sub> is a chimera likely constructed in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2012;56:2773-6
12. Kamruzzaman M, Patterson JD, Shoma S, Ginn AN, Partridge SR, Iredell JR. Relative Strengths of Promoters Provided by Common Mobile Genetic Elements Associated with Resistance Gene Expression in Gram-Negative Bacteria. *Antimicrob Agents Chemother.* 2015;59:5088-91
13. Findlay J, Hopkins KL, Alvarez-Buylla A, Meunier D, Mustafa N, Hill R, Pike R, McCrae LX, Hawkey PM, Woodford N. Characterization of carbapenemase-producing Enterobacteriaceae in the West Midlands region of England: 2007-14. *J Antimicrob Chemother.* 2017;72:1054-1062
14. Bahr G, Vitor-Horen L, Bethel CR, Bonomo RA, González LJ, Vila AJ. Clinical Evolution of New Delhi Metallo- $\beta$ -Lactamase (NDM) Optimizes Resistance under Zn(II) Deprivation. *Antimicrob Agents Chemother.* 2017;62. pii: e01849-17
15. Stewart AC, Bethel CR, VanPelt J, Bergstrom A, Cheng Z, Miller CG, Williams C, Poth R, Morris M, Lahey O, Nix JC, Tierney DL, Page RC, Crowder MW, Bonomo



- RA, Fast W. Clinical Variants of New Delhi Metallo- $\beta$ -Lactamase Are Evolving To Overcome Zinc Scarcity. *ACS Infect Dis.* 2017;3:927-940
16. Ito H, Arakawa Y, Ohsuka S, Wacharotayankun R, Kato N, Ohta M. Plasmid-mediated dissemination of the metallo-beta-lactamase gene *bla<sub>IMP</sub>* among clinically isolated strains of *Serratia marcescens*. *Antimicrob Agents Chemother.* 1995;39:824-9.
17. Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN. Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. *Open Forum Infect Dis.* 2019;6(Suppl 1):S23-S33.
18. López C, Ayala JA, Bonomo RA, González LJ, Vila AJ. Protein determinants of dissemination and host specificity of metallo- $\beta$ -lactamases. *Nat Commun.* 2019;10:3617.
19. Schirch V, Hopkins S, Villar E, Angelaccio S. Serine hydroxymethyltransferase from *Escherichia coli*: purification and properties. *J Bacteriol.* 1985;163:1-7.
20. Lam HM, Winkler ME. Metabolic relationships between pyridoxine (vitamin B6) and serine biosynthesis in *Escherichia coli* K-12. *J Bacteriol.* 1990;172:6518-28.
21. Thèze J, Saint-Girons I. Threonine locus of *Escherichia coli* K-12: genetic structure and evidence for an operon. *J Bacteriol.* 1974;118:990-8.
22. Calhoun DH, Gray JE. Cloning of the *ilvA538* gene coding for feedback-hypersensitive threonine deaminase from *Escherichia coli* K-12. *J Bacteriol.* 1982;151:274-80.
23. Alorabi M, AlAmri AM, Takebayashi Y, Heesom KJ, Avison MB. Synonymous lysine codon usage modification in a mobile antibiotic resistance gene similarly

alters protein production in bacterial species with divergent lysine codon usage biases because it removes a duplicate AAA lysine codon bioRxiv 2018; doi: <https://doi.org/10.1101/294173>.

24. Chen CJ, Wu TL, Lu PL, Chen YT, Fung CP, Chuang YC, Lin JC, Siu LK. Closely related NDM-1-encoding plasmids from *Escherichia coli* and *Klebsiella pneumoniae* in Taiwan. PLoS One. 2014;9:e104899.

25. Wailan AM, Sartor AL, Zowawi HM, Perry JD, Paterson DL, Sidjabat HE. Genetic Contexts of *bla*<sub>NDM-1</sub> in Patients Carrying Multiple NDM-Producing Strains. Antimicrob Agents Chemother. 2015;59:7405-10.

26. Perry JD, Naqvi SH, Mirza IA, Alizai SA, Hussain A, Ghirardi S, Orena S, Wilkinson K, Woodford N, Zhang J, Livermore DM, Abbasi SA, Raza MW. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother. 2011;66:2288-94.

27. Jiménez-Castellanos JC, Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Schneiders T, Heesom KJ, Avison MB. Envelope proteome changes driven by RamA overproduction in *Klebsiella pneumoniae* that enhance acquired  $\beta$ -lactam resistance. J Antimicrob Chemother. 2018;73:88-94.

28. Göttig S, Riedel-Christ S, Saleh A, Kempf VA, Hamprecht A. Impact of *bla*<sub>NDM-1</sub> on fitness and pathogenicity of *Escherichia coli* and *Klebsiella pneumoniae*. Int J Antimicrob Agents. 2016;47:430-5.

29. González LJ, Bahr G, Nakashige TG, Nolan EM, Bonomo RA, Vila AJ. Membrane anchoring stabilizes and favors secretion of New Delhi metallo- $\beta$ -lactamase. Nat Chem Biol. 2016 ;12:516-22.

30. Bilinskaya A, Buckheit DJ, Gnoinski M, Asempa TE, Nicolau DP. Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo- $\beta$ -Lactamase-Producing Enterobacteriaceae. J Clin Microbiol. 2020 ;58:e02019-20.
31. Arnaud J, Touvier M, Galan P, Andriollo-Sanchez M, Ruffieux D, Roussel AM, Hercberg S, Favier A.. Determinants of serum zinc concentrations in a population of French middle-age subjects (SU.VI.MAX cohort). Eur J Clin Nutr. 2010;64:1057-64.
32. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582-610.
33. Guyer MS, Reed RR, Steitz JA, Low KB. Identification of a sex-factor-affinity site in *E. coli* as gamma delta. Cold Spring Harb Symp Quant Biol. 1981;45:135-40.
34. Jiménez-Castellanos JC, Wan Ahmad Kamil WN, Cheung CH, Tobin MS, Brown J, Isaac SG, Heesom KJ, Schneiders T, Avison MB. Comparative effects of overproducing the AraC-type transcriptional regulators MarA, SoxS, RarA and RamA on antimicrobial drug susceptibility in *Klebsiella pneumoniae*. J Antimicrob Chemother. 2016;71:1820-5.
35. Martinez E, Bartolomé B, de la Cruz F. pACYC184-derived cloning vectors containing the multiple cloning site and *lacZ* alpha reporter gene of pUC8/9 and pUC18/19 plasmids. Gene. 1988;68:159-62.
36. Brem J, Cain R, Cahill S, McDonough MA, Clifton IJ, Jiménez-Castellanos JC, Avison MB, Spencer J, Fishwick CW, Schofield CJ. Structural basis of metallo- $\beta$ -lactamase, serine- $\beta$ -lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun. 2016;7:12406.

37. Takebayashi T, Wan Nur Ismah WAK, Findlay J, Heesom KJ, Zhang J, Williams OM, MacGowan AP, Avison MB. Prediction of cephalosporin and carbapenem susceptibility in multi-drug resistant Gram-negative bacteria using liquid chromatography-tandem mass spectrometry. *bioRxiv* 2017; doi: <https://doi.org/10.1101/138594>
38. Bennett AF, Lenski RE. Evolutionary adaptation to temperature II. Thermal niches of experimental lines of *Escherichia coli*. *Evolution*. 1993;47:1-12.
39. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014;30:2114-20.
40. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol*. 2012;19:455-77.
41. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 2014;30:2068-9.
42. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 2014;58:3895–903.
43. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother*. 2012;67:2640-4.

**Table 1. Fitness effect of carrying *bla*<sub>IMP-1</sub> or *bla*<sub>NDM-1</sub> in *E. coli* and *K. pneumoniae***

<b>Strain</b>	<b>Competition</b>	<b>Mean fitness (W)</b>	<b>+/- SEM</b>
<b><i>E. coli</i> MG1655</b>	pSU18 vs pSUH IMP	+4.5	0.5
	pSU18 vs pSU NDM	-8.0	0.4
	pSU18 vs pSUH IMP-KV	-1.9	0.5
<b><i>K. pneumoniae</i> ECL8</b>	pSU18 vs pSUH IMP	+5.9	0.6
	pSU18 vs pSU NDM	-29.3	0.7
	pSU18 vs pSUH IMP-KV	-13.6	2.2

## Figure Legends

### Figure 1. MBL Production in Enterobacterales carrying *bla*<sub>IMP-1</sub> or *bla*<sub>NDM-1</sub> with variant upstream sequences.

MBL production was measured in *K. pneumoniae*, *E. coli* or *K. aerogenes* (*Ent. aerogenes*) recombinants carrying the pSU18 cloning vector, into which had been ligated *bla*<sub>IMP-1</sub> with its upstream Pc(H1) promoter (dark blue bars), *bla*<sub>NDM-1</sub> with its wild-type IS*Aba125* promoter (bed bars), *bla*<sub>NDM-1</sub> with site directed mutation to convert its ribosome binding site to be identical to that upstream of *bla*<sub>IMP-1</sub> (N RBS, light blue bars), and *bla*<sub>NDM-1</sub> synthesised to have the same upstream sequence as *bla*<sub>IMP-1</sub> (N\*, purple bars). In (A) meropenem hydrolysing activity (nmol.min<sup>-1</sup>.mg total protein<sup>-1</sup>) was measured in whole cell extracts. In (B) IMP-1 or NDM-1 protein abundance derived from LC-MS/MS analysis of whole cell extracts is reported normalised to the average abundance of 30S and 50S ribosomal proteins in each extract. Data are means +/- Standard Error of the Mean, n=3.

### Figure 2. Increased production of IMP-1 following introduction of 17 AAA-AAG lysine codon variants into *bla*<sub>IMP-1</sub>.


*E. coli* MG1655 recombinants carry pSU18 with *bla*<sub>IMP-1</sub> or a variant (22) in which 17 AAA lysine codons had been mutated to AAG (IMP-1-KV) were analysed. IMP-1 protein abundance derived from LC-MS/MS analysis of whole cell extracts is reported normalised to the average abundance of 30S and 50S ribosomal proteins in each extract. Data are means +/- Standard Error of the Mean, n=3.

**Figure 3. Altered Upstream Sequence in Ent1/2 and KP3 versus *bla*<sub>NDM-1</sub> Source Sequences.**


The Clustal Omega alignment used WGS data from two isolates carrying wild-type *bla*<sub>NDM-1</sub>: *E. coli* IR10 and *K. pneumoniae* KP05-506 plus the sequence shared by clinical isolates Ent1, Ent 2 and KP3. Identities across all three sequences are annotated with stars.

Figure 1

A




B





**Figure 2**



KP05_506	-----acaccattagagaaatgtgctcagcttgattatcatatggcttttgaaac	53
IR10	-----acaccattagagaaatgtgctcagcttgattatcatatggcttttgaaac	53
Ent1	ccagctaatagccgta---ctcgaaagacagcttgattatcatatggcttttgaaac	56
	*   *   *	
	*****	
KP05_506	tgtcgcacctcatgtttgaattcgccccatatTTTTGCTACAGTGAACCAATTAAGATC	113
IR10	tgtcgcacctcatgtttgaattcgccccatatTTTTGCTACAGTGAACCAATTAAGATC	113
Ent1	tgtcgcacctcatgtttgaattcgccccatatTTTTGCTACAGTGAACCAATTAAGATC	116
	*****	